CNCR Holdings
Loncar Cancer Immunotherapy ETF
1W: +0.0%
1M: -11.3%
3M: -16.4%
1Y: -38.1%
3Y: -36.0%
5Y: -62.0%
$9.02
Last traded 2025-06-03 — delisted
Overview
Chart
Holdings
Changes
Technicals
Analysis
Peers
Institutions
Dark Pool
Short Interest
Dividends
Weather
ETF-Level Metrics
AUM$7M
Holdings31
Top 10 Wt34.4%
Beta0.96
% Profitable29%
Coverage97%
Portfolio Valuation
P/E35.1
P/B6.0
P/S4.6
EV/EBITDA20.1
P/FCF19.4
PEG10.61
Profitability & Returns
Gross Margin78.4%
Net Margin10.0%
ROE12.4%
ROA5.2%
ROIC10.3%
Div Yield0.39%
Leverage & Liquidity
Debt/Equity0.90
Debt/Assets0.36
Net Debt/EBITDA1.8x
Interest Cov6.5x
Current Ratio1.51
Quick Ratio1.29
Growth (YoY)
Revenue+10.8%
Net Income+12.1%
EPS+21.7%
FCF+11.8%
EBITDA+7.5%
Rev CAGR 3Y+115.2%
Quality Scores
Piotroski F4.0
Altman Z-5.44
IS Quality50.6
IS Overall38.2
IS Value37.8
Median P/E-4.1
Sector Breakdown
3 sectors| Sector | # Holdings | Total Weight % | Avg P/E |
|---|---|---|---|
| Healthcare | 29 | 96.6% | -0.2 |
| Financial Services | 1 | 3.3% | — |
| Other | 1 | 0.1% | — |
Smart Money Overlap
1 holdings with signals| Symbol | Company | Weight % | Signals | Badge | Insider Buys | Congress | Since Signal |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca PLC | 3.39% | 4 | Bullish | 1 | 2 | -2.8% |
Showing 31 of 31 holdings
· Page 1 of 1
| # | Name | Ticker | Weight % ▼ | Mkt Value | Shares | P/E | Mkt Cap | Sector |
|---|---|---|---|---|---|---|---|---|
| 1 | Instil Bio, Inc. | TIL | 3.59% | $963,402 | 93,230 | -1.6 | $49M | Healthcare |
| 2 | Replimune Group, Inc. | REPL | 3.54% | $949,984 | 47,193 | -4.1 | $1.1B | Healthcare |
| 3 | Iovance Biotherapeutics, Inc. | IOVA | 3.47% | $931,199 | 67,485 | -20.3 | $6.3B | Healthcare |
| 4 | Zymeworks Inc. | ZYME | 3.45% | $925,832 | 41,554 | -12.5 | $1.9B | Healthcare |
| 5 | argenx SE | ARGX | 3.42% | $917,781 | 5,056 | 33.0 | $57.2B | Healthcare |
| 6 | Genmab A/S | GMAB | 3.42% | $917,781 | 35,793 | 26.3 | $21.3B | Healthcare |
| 7 | AstraZeneca PLC | AZN | 3.39% | $909,731 | 26,541 | 23.3 | $243.3B | Healthcare |
| 8 | Bristol-Myers Squibb Company | BMY | 3.39% | $909,731 | 23,173 | 13.5 | $124.9B | Healthcare |
| 9 | CRISPR Therapeutics AG | CRSP | 3.39% | $909,731 | 12,623 | -11.6 | $5.3B | Healthcare |
| 10 | Xencor, Inc. | XNCR | 3.37% | $904,363 | 41,933 | -11.4 | $1.8B | Healthcare |
| 11 | Nektar Therapeutics | NKTR | 3.37% | $904,363 | 87,535 | -6.5 | $1.3B | Healthcare |
| 12 | Merck & Co., Inc. | MRK | 3.37% | $904,363 | 20,509 | 114.5 | $356.4B | Healthcare |
| 13 | Regeneron Pharmaceuticals, Inc. | REGN | 3.36% | $901,680 | 2,936 | 17.6 | $75.7B | Healthcare |
| 14 | Fate Therapeutics, Inc. | FATE | 3.33% | $893,629 | 17,661 | -2.2 | $270M | Healthcare |
| 15 | Gilead Sciences, Inc. | GILD | 3.33% | $893,629 | 22,538 | -55.7 | $179.5B | Healthcare |
| 16 | Arcus Biosciences, Inc. | RCUS | 3.32% | $890,946 | 62,765 | -6.2 | $3.1B | Healthcare |
| 17 | Atara Biotherapeutics, Inc. | ATRA | 3.30% | $885,578 | 108,596 | -8.0 | $85M | Healthcare |
| 18 | Trillium Therapeutics Inc. | TRIL | 3.29% | $882,895 | 160,991 | — | $1M | Financial Services |
| 19 | Allogene Therapeutics, Inc. | ALLO | 3.29% | $882,895 | 60,621 | -2.2 | $518M | Healthcare |
| 20 | Rubius Therapeutics, Inc. | RUBY | 3.29% | $882,895 | 59,286 | -0.0 | — | Healthcare |
| 21 | ImmunityBio, Inc. | IBRX | 3.28% | $880,211 | 104,736 | -10.6 | $10.8B | Healthcare |
| 22 | bluebird bio, Inc. | BLUE | 3.28% | $880,211 | 46,078 | -0.2 | $49M | Healthcare |
| 23 | I-Mab | IMAB | 3.25% | $872,161 | 21,296 | -4.6 | $542M | Healthcare |
| 24 | Shattuck Labs, Inc. | STTK | 3.23% | $866,793 | 53,960 | -13.2 | $608M | Healthcare |
| 25 | IGM Biosciences, Inc. | IGMS | 3.23% | $866,793 | 16,717 | -0.4 | $77M | Healthcare |
| 26 | ALX Oncology Holdings Inc. | ALXO | 3.21% | $861,426 | 25,591 | -1.1 | $164M | Healthcare |
| 27 | Legend Biotech Corporation | LEGN | 3.20% | $858,743 | 38,005 | -37.1 | $3.4B | Healthcare |
| 28 | BeiGene, Ltd. | BGNE | 3.19% | $856,059 | 4,424 | 3.6 | $20.2B | Healthcare |
| 29 | MacroGenics, Inc. | MGNX | 3.17% | $850,692 | 71,307 | -16.3 | $228M | Healthcare |
| 30 | Y-mAbs Therapeutics, Inc. | YMAB | 3.12% | $837,274 | 41,609 | -12.9 | $391M | Healthcare |
| 31 | — Private | Cash&Other | 0.13% | $34,886 | 60,864 | — | — | — |